

Graphical Abstract. 4-deoxyphorbol A inhibits HIV-1 infection and reactivates viral reservoirs through PKC/MEK/NF-κB activation and synergizes with vorinostat and antiretroviral drugs.

Figure 1







Figure 2



B





Figure 3

A



B





Figure 4

MT-2



PBMCs




Figure 5






Figure 6

A)



B)



C)




Figure 7





Figure 8







Figure 9



Combination Index Values at

Drug combination	EC ₅₀	EC ₇₅	EC ₉₀
Prostratin + Vorinostat (39.1:1)	0.20	0.23	0.25
Vorinostat + 4β-dPE A (32:1)	0.21	0.21	0.21
Prostratin + 4β-dPE A (1250:1)	16.65	110.90	739.48



Combination Index Values at

Drug combination	EC ₅₀	EC ₇₅	EC ₉₀
4β-dPE A/ABC (1:240)	0,48	0,41	0,36
4β-dPE A/3TC (1:200)	0,48	0,37	0,28
4β-dPE A/EFV (5:1)	0,78	0,84	0,90
4β-dPE A/FTC (1:70)	0,40	0,30	0,22
4β-dPE A/Rito (1:10)	0,63	0,59	0,62
4β-dPE A/TFV (1:300)	0,47	0,36	0,30
4β-dPE A/MVC (1:3)	0,58	0,69	0,87

Figure 10

Figure 11




Figure 12




Figure 13

